NCT06877247View on ClinicalTrials.gov

A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 19, 2024

Primary Completion Date

April 4, 2025

Study Completion Date

September 30, 2025

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

[14C] SHR6508 Injection

\[14C\] SHR6508 injection.

Trial Locations (1)

250014

The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province), Jinan

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

NCT06877247 - A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism | Biotech Hunter | Biotech Hunter